What Is 3-Hydroxy-3-methylglutaryl-coenzyme A

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) is an intermediate molecule in the mevalonate pathway, crucial for cholesterol synthesis. It is formed from acetyl-CoA and acetoacetyl-CoA and is the substrate for HMG-CoA reductase, the enzyme targeted by statin drugs since the 1980s.

Key Facts

HMG-CoA was first identified in the 1950s during studies of cholesterol biosynthesis
The enzyme HMG-CoA reductase is the rate-limiting step in cholesterol production
Statins inhibit HMG-CoA reductase, reducing cholesterol by 20–60%
HMG-CoA is a 232.2 g/mol molecule with the chemical formula C21H32N7O18P3S
Two pathways produce HMG-CoA: cytosolic (for cholesterol) and mitochondrial (for ketones)

Overview

3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) is a critical metabolic intermediate in both cholesterol and ketone body synthesis. It plays a central role in the mevalonate pathway, which occurs primarily in the liver and is essential for producing cholesterol and other isoprenoids.

Discovered in the 1950s, HMG-CoA became a major focus of biochemical research due to its regulatory significance. Its conversion to mevalonate by HMG-CoA reductase is the primary control point for cholesterol biosynthesis, making it a key pharmaceutical target.

Chemical structure: HMG-CoA consists of a 3-hydroxy-3-methylglutarate moiety linked to coenzyme A via a thioester bond, with a molecular weight of 232.2 g/mol.
Formation: It is synthesized from acetyl-CoA and acetoacetyl-CoA by the enzyme HMG-CoA synthase in a reaction that occurs in both mitochondria and cytosol.
Metabolic pathways: HMG-CoA serves as a branch point: in the cytosol, it leads to cholesterol; in mitochondria, it leads to ketogenesis.
Discovery timeline: First isolated in 1956 by Feodor Lynen and Konrad Bloch, whose work earned them the 1964 Nobel Prize in Physiology or Medicine.
Biological significance: As the immediate precursor to mevalonate, HMG-CoA is essential for the production of sterols, dolichols, ubiquinone, and prenylated proteins.

How It Works

HMG-CoA functions as a pivotal intermediate by channeling metabolic flux toward either cholesterol or ketone bodies, depending on cellular conditions such as energy status and insulin levels.

Enzyme: HMG-CoA reductase This enzyme catalyzes the NADPH-dependent reduction of HMG-CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. It is highly regulated by feedback inhibition and gene expression.
Statins mechanism Drugs like atorvastatin and simvastatin competitively inhibit HMG-CoA reductase, lowering serum cholesterol by 20–60% and reducing cardiovascular risk.
Subcellular localization Cytosolic HMG-CoA is used for cholesterol synthesis, while mitochondrial HMG-CoA is converted to acetoacetate during fasting or diabetes.
Regulation The enzyme is regulated by phosphorylation (inactivation) and dephosphorylation (activation), as well as by degradation in response to high sterol levels.
Gene expression The HMGCR gene is transcriptionally controlled by SREBP-2, which activates cholesterol synthesis genes when cellular levels are low.
Feedback inhibition Cholesterol and other sterols suppress HMG-CoA reductase activity, preventing overproduction through a negative feedback loop.

Comparison at a Glance

The following table compares HMG-CoA's roles in cholesterol synthesis versus ketogenesis:

Feature	Cholesterol Pathway	Ketogenesis Pathway
Location	Cytosol of liver and other tissues	Mitochondria of liver cells
Primary enzyme	HMG-CoA reductase	HMG-CoA lyase
End product	Cholesterol, steroid hormones, bile acids	Acetoacetate, β-hydroxybutyrate, acetone
Regulated by	Insulin, SREBP-2, sterol levels	Glucagon, low insulin, fasting
Therapeutic target	Statins inhibit HMG-CoA reductase	No major drugs target this pathway directly

This dual role underscores HMG-CoA’s metabolic versatility. While cholesterol synthesis supports cell membrane integrity and hormone production, ketogenesis provides alternative fuel during prolonged fasting or in uncontrolled diabetes, highlighting the molecule’s physiological importance in both fed and fasted states.

Why It Matters

Understanding HMG-CoA is vital for both basic biochemistry and clinical medicine, particularly in managing cardiovascular disease and metabolic disorders. Its central role in cholesterol regulation has made it one of the most studied intermediates in human metabolism.

Cardiovascular health: Lowering HMG-CoA reductase activity with statins reduces LDL cholesterol and prevents over 70,000 heart attacks annually in the U.S.
Drug development: Statins, introduced in 1987 with lovastatin, are among the most prescribed drugs globally, generating over $15 billion in annual sales at peak.
Metabolic diseases: Deficiencies in HMG-CoA lyase cause a rare inherited disorder leading to life-threatening acidosis in infants.
Biotechnology: Engineered yeast strains use the mevalonate pathway to produce artemisinin, an antimalarial drug, via synthetic biology.
Nutritional implications: Low-carb diets increase mitochondrial HMG-CoA flux, boosting ketone production for brain energy during ketosis.
Evolutionary role: The mevalonate pathway is conserved across eukaryotes, indicating its fundamental role in cellular metabolism.

From Nobel Prize-winning discoveries to life-saving medications, HMG-CoA exemplifies how understanding a single metabolic intermediate can transform medicine and public health.